kinase kinase) and extracellular signal regulated kinases (ERK) Peroxisome proliferators (PPs) are a class of non-genotoxic pathway is primarily responsible for responding to cellular chemicals that cause rodent liver enlargement and hepatoproliferation signals, while the p38 MAP kinases and c-Jun carcinogenesis. In primary rat hepatocytes, PPs cause cell N-terminal kinases (JNK) respond to cellular stress signals (15-proliferation, suppression of apoptosis and peroxisome 17). p38 MAP kinases are key mediators of the inflammatory proliferation. We have investigated the role of different response and are activated by cytokines, growth factors and a families of mitogen-activated protein (MAP) kinases in the variety of cellular stresses, including heat shock, ionizing mode of action of PPs. Addition of 50 µM nafenopin to radiation, UV radiation and hyperosmolarity (18, 19) . Activaprimary rat hepatocyte cultures caused weak activation of tion of both the p38 and the ERK families of MAP kinases extracellular signal regulated kinases and p38 MAP kinase.
Introduction
Insight Biotechnologies Ltd, transforming growth factor β 1 (TGF-β 1 ), 7-amino-4-methyl-coumarin (AMC), actinomycin D and epidermal growth Peroxisome proliferators (PPs) are a class of non-genotoxic factor (EGF) from Sigma, UK. Bromodeoxyuridine (BrdU)-labelling reagents carcinogens that cause peroxisome proliferation and tumours were purchased from Sigma, UK and the anti-BrdU antibody from Roche, UK.
in rodent liver. The induction of DNA synthesis and suppression All other tissue culture reagents were purchased from Life Technologies, UK.
of apoptosis are implicated in the mechanism of carcinogenicity Cell culture and treatment for these structurally diverse compounds (1-4). The action of Primary rat hepatocyte cultures were prepared as follows: at termination, rats PPs in rodents is mediated via activation of the peroxisome were subject to terminal anaesthesia with ether and hepatocytes isolated by a proliferator activated receptor α (PPARα), a ligand-activated two-step collagenase perfusion (24) using 0.05% (w/v) collagenase. Hepatotranscription factor that can cause transcriptional regulation of cytes (2ϫ10 6 viable cells) were inoculated into tissue culture flasks in Williams medium E supplemented with 10% fetal calf serum, 10 µg/ml insulin, 0.1 mM genes associated with peroxisome proliferation and fatty acid hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin, 0.01% BSA and β-oxidation (5,6). 100 µg/ml streptomycin. Cultures were maintained at 37°C in a humidified
The mechanisms by which PPs perturb liver growth are atmosphere and medium was changed after 4 h. MAP kinase inhibitors unknown but may involve the pro-inflammatory cytokine SB203580 (10 µM) and PD098059 (20 µM) were added 2 h prior to addition of nafenopin which was used at a concentration of 50 µM in order to avoid tumour necrosis factor α (TNF-α) (7,8). TNF-α is produced toxicity. In apoptosis experiments, 5 ng/ml TGF-β 1 was added 8 h after mainly by activated macrophages and in smaller amounts by addition of nafenopin.
other cell types (9,10). Kupffer cells, the resident hepatic Western blotting macrophages, are a rich source of cytokines in the liver (11, 12) Cells were lysed in Buffer A (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na 3 VO 4 , 0.1% 2-mercaptoethanol, 1% Triton X-100, 50 mM sodium fluoride, 5 mM sodim pyrophosphate, 10 mM sodium β-glycerophosAbbreviations: AMC, 7-amino-4-methyl-coumarin; BrdU, bromodeoxyuridine; CIPCO, cyanide-insensitive palmitoyl CoA oxidation; EGF, epidermal phate, 0.1 mM PMSF, 1 µg/ml aprotinin, leupeptin, pepstatin). Hepatocyte lysates (50 µg protein/sample) were mixed with NuPAGE sample buffer growth factor; MAP kinase, mitogen-activated kinase; PP, peroxisome proliferator; PPAR, peroxisome proliferator activated receptor; TGF-β 1 , trans-(Novex) and run on NuPAGE Bis-Tris polyacrylamide gels (Novex) according to the manufacturer's instructions. Equal loading was verified by Ponceau S forming growth factor β 1 ; TNF-α, tumour necrosis factor α. solution staining (Sigma). Western blotting was carried out using PVDF membranes and anti-phospho-p44/42 MAP kinase antibodies (New England Biolabs).
Measurement of apoptosis and S-phase
Apoptosis. Sixteen hours after addition of TGF-β 1 , the monolayers were fixed with ice-cold methanol for 5 min and then stained with Hoechst 33258 (5 ng/ml) as described previously (25) . Cells were then washed in distilled water and mounted in a solution of 20 mM citric acid, 50 mM disodium orthophosphate and 50% glycerol. Apoptotic cells were scored by nuclear morphology. S-phase. Eight hours after treatment with nafenopin, cells were incubated with BrdU for a further 16 h. Monolayers were then washed, fixed and incubated in the presence of anti-BrdU antibody. Incorporated BrdU was localized using peroxidase-linked secondary antibody and a diaminobenzidine (DAB) substrate as described previously (25) . DNA synthesis was measured by scoring the number of DAB stained nuclei. More than 1000 cells were counted for each flask.
p38 activity assays p38 MAP kinase activity assays were carried out using an Upstate Biotechnology MAPKAP kinase 2 immunoprecipitation-kinase assay kit, according to the manufacturer's instructions and using [ 33 P]dATP (Amersham, UK). After transfer on P81 phosphocellulose paper, samples were read on a scintillation counter. MAPKAP kinase 2 substrate peptide was also obtained from treated with DMF, 50 µM nafenopin or 10 ng/ml EGF for the times indicated, before lysis, SDS-PAGE and western blotting using phospho p42/ Cells were washed in PBS, scraped in ice-cold PBS and pelleted by p44 (ERK1 and ERK2) MAP kinase antibodies. (B) p38 MAP kinase centrifugation at 2000 r.p.m. for 2 min. The cell pellet was then resuspended activation. MAPKAP-kinase 2 was immunoprecipitated from primary rat in TES (20 mM Tris-HCl pH 7.4, 5 mM EDTA, 250 mM sucrose), disrupted hepatocyte lysates treated with 5 ng/ml TNF-α or nafenopin (50 µM) for 5 by sonication and stored at -70°C for CIPCO and protein assays. CIPCO and 60 min in the presence or absence of SB203580 (20 µM) as indicated. assays were carried out as described previously (26) with some modifications.
MAPKAP-kinase 2 activity was measured as described in Materials and The assay medium contained 60 mM Tris-HCl pH 8.3, 50 µM Co enzyme methods. Results are expressed as mean arbitrary units/µg protein and are A, 370 µM NAD ϩ , 94 mM nicotinamide, 2.8 mM dithiothreitol, 2 mM KCN, reported as means Ϯ SD. 12.5 µg/ml bovine serum albumin (fatty acid free), 100 µg/ml flavin adenosine dinucleotide, 50 µg/ml palmitoyl CoA. Protein concentration in the CIPCO assay aliquot of each sample was assessed using Bio-Rad Bradford protein assay reagent following the manufacturer's instructions. CIPCO activity was conditions, however, nafenopin only weakly activated p38 expressed as nmol NAD ϩ reduced/min/mg protein.
MAP kinase (Figure 1B). In agreement with previous studies
Caspase-3 activity assays (17), the basal levels of p38 MAP kinase were found to be Caspase-3 activity in cytosols was prepared using the method outlined in high in primary rat hepatocytes compared with other cell lines Swanton et al. (27) . Cytosols (20 µg) were then incubated with 50 µM (not shown).
Ac-DEVD-AMC for 10 min at room temperature. Using these conditions,
Inhibition of MAP kinases prevents the suppression of apoptosis
AMC release was found to be within the linear range. Samples were diluted to 2 ml in water and the generation of fluorescent product determined using by the PP nafenopin an SLM Aminco fluorimeter.
As described previously (25) , addition of the PP nafenopin to
Measurement of TNF-α levels
primary rat hepatocyte cultures results in the suppression of L929 cells were seeded in 96-well plates (2.5ϫ10 4 /well) and grown at spontaneous apoptosis and that induced by TGF-β 1 . Inhibition 37°C/5% CO 2 . Twenty-four hours later 6 µg/ml actinomycin D was added, of TGF-β 1 -induced apoptosis by nafenopin was measured by 1 h before the addition of 100 µl of medium from hepatocyte cultures. Plates scoring changes in nuclear morphology (Figure 2A and B) were further incubated at 37°C/5% CO 2 for 18 h. After incubation, the medium was removed before addition of 100 µl crystal violet solution (0.2% in 2%
and by measuring activation of caspases using cytosolic extracts ethanol). Plates were washed in water, dried and incubated in 1% SDS before from hepatocyte cultures ( Figure 2C ). In both cases, nafenopin measuring OD at 620 nm. Standard concentrations of TNF-α were used on suppressed TGF-β 1 -induced apoptosis by~50%.
each individual plate to generate a standard curve.
To investigate the role of MAP kinase signalling pathways in the suppression of apoptosis by PPs, we evaluated the Results effects of SB203580 and PD098059 on the response of primary rat hepatocytes to the PP nafenopin. Addition of the p38 MAP The PP nafenopin weakly activates ERK MAP kinase and p38 kinase inhibitor SB203580 or the MEK inhibitor PD098059 MAP kinase did not affect the levels of spontaneous apoptosis (not shown) To establish whether nafenopin activated different MAP kinases or TGF-β 1 -induced apoptosis (Figure 2A and B) . However, directly in primary rat hepatocyte cultures, we analysed the pre-treatment of primary rat hepatocyte cultures with SB203580 phosphorylated forms of ERK and p38 MAP kinases. Western or PD098059 prevented the suppression of TGF-β 1 -induced blotting using antibodies specific for the phosphorylated form apoptosis by nafenopin (Figure 2A 
and B). of ERK MAP kinases showed strong activation of ERK MAP MAP kinase inhibitors prevent the induction of S-phase by the kinase in primary rat hepatocytes upon treatment with EGF
PP nafenopin ( Figure 1A) . However, weak activation of ERK MAP kinase was observed upon treatment with 50 µM nafenopin (Figure PPs cause cell replication in isolated rat hepatocytes. To determine whether induction of S-phase by the PP nafenopin 1A). Treatment of primary rat hepatocyte cultures with TNF-α resulted in a 2-3-fold increase in p38 activity (measured by was dependent on MAP kinases, we treated primary rat hepatocytes with SB203580 or PD098059. Stimulation of activation of MAPKAP-K2 kinase) ( Figure 1B) . Under these Results were converted to nmol NAD ϩ reduced/min/mg of protein.
primary rat hepatocytes with nafenopin in the presence of SB203580 prevents TNF-α production in response to PPs SB203580 or PD098059, prevented the PP-induced increase in S-phase (Figure 3 ). This suggests that MAP kinase activity p38 MAP kinase has been implicated in the regulation of TNF-α production in monocytes and other cell types (28). is required for primary hepatocytes to undergo S-phase in response to PPs.
We therefore evaluated the effects of SB203580 on TNF-α production in hepatocyte cultures in response to PP treatment.
Inhibition of MAP kinases does not affect CIPCO
Levels of bioactive TNF-α were found to increase in primary Because MAP kinase inhibitors affected the regulation of cell rat hepatocytes in response to treatment with nafenopin growth by PPs, we examined whether MAP kinases were also ( Figure 5 ). This increase was inhibited when cultures were involved in peroxisome proliferation. CIPCO measurements pre-treated with SB203580 ( Figure 5 ), indicating that p38 were used as an indicator of fatty acid β-oxidation associated MAP kinase activity is required for the release of bioactive with peroxisome proliferation. As expected, nafenopin gave a TNF-α in response to PPs. strong induction of β-oxidation of palmitoyl CoA in this system, but this was unaffected by the presence of MAP kinase Discussion inhibitors (Figure 4) . Therefore, inhibition of MAP kinases did not affect the induction of fatty acid β-oxidation by
The mechanisms by which PPs regulate cellular proliferation and survival are still not known. In this study, we have nafenopin.
for PPARα-mediated transcriptional activation of genes required for peroxisome proliferation, we cannot exclude a role for MAP kinases in PPARα-mediated transcription of genes involved in growth regulation.
The inhibition of PP-mediated growth effects by MAP kinase inhibitors shown here, may be the result of indirect effects on signalling pathways triggered by cytokines and growth factors. The p38 MAP kinase inhibitor SB203580 has been shown to have anti-inflammatory properties and to inhibit the production of cytokines, including TNF-α, IL-1 and IL-6 (20, 27, 35) . Indeed, in primary hepatocyte cultures, SB203580 prevented the increase in bioactive TNF-α levels induced by treatment with the PP nafenopin. These findings support a role for TNF-α and perhaps other hepatic cytokines, as mediators of the growth regulatory effects of PPs. In addition, our results MAP kinase by mitogens or cytokines such as TNF-α may be required for the growth changes to occur. Induction of oxidative stress by PPs (14, 36) may also play a role in the activation investigated the role of intracellular signalling via different MAP kinases in the mode of action of PPs. Using specific MAP kinase pathways. In particular, p38 MAP kinase has been associated with oxidative stress (18, 37) and has been inhibitors, we show that inhibition of different families of MAP kinases prevents the induction of S-phase and suppression reported to be constitutively active in mouse liver (19) . Although the ability of the PP class of rodent hepatocarcinogof apoptosis by the PP nafenopin but does not prevent peroxisome proliferation. As TNF-α is thought to be a key ens to cause hepatic cell proliferation and survival have been described extensively, the molecular mechanisms responsible mediator of the response to PPs, we show that one of the functions of MAP kinase signalling pathways may be to for this perturbation are still unclear. Here we demonstrate that the PP-induced regulation of cell growth and apoptosis regulate the levels of this cytokine in the liver. Therefore, activation of distinct families of MAP kinases by different involves different molecular mechanisms from the induction of peroxisome proliferation. hepatic factors may play a permissive role in growth perturbation by PPs.
It has previously been shown that treatment of immortalized References liver cell lines and rat hepatocytes with the PP Wy- 14, 643 activation domain in PPARα has been shown to contain MAP we have established that MAP kinase activity is not required
